LGR4 and neoplasm: By developing monoclonal antibodies and small molecule inhibitors against LGR4, we can inhibit the growth and metastasis of tumor cells in bone tissues, alleviate patients’ pain and skeletal complications, and improve patients’ survival rate and quality of life.